Efficacy and safety of chemoradiotherapy combined with regional hyperthermia for elderly patients with cervical cancer(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2026年第6期
- Page:
- 727-731
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Efficacy and safety of chemoradiotherapy combined with regional hyperthermia for elderly patients with cervical cancer
- Author(s):
- HE Li; SU Jin; QIAN Yingjing; LIU Yan; YAN Qing; GAO Ying
- Department of Radiotherapy, the First Affiliated Hospital of Xian Jiaotong University, Xian 710061, China
- Keywords:
- Keywords: cervical cancer elderly patient chemoradiotherapy regional hyperthermia safety
- PACS:
- R319；R737.33；R816.93
- DOI:
- DOI:10.3969/j.issn.1005-202X.2026.06.004
- Abstract:
- Abstract: Objective To investigate the efficacy and safety of chemoradiotherapy combined with regional hyperthermia in the treatment of elderly patients with cervical cancer. Methods A total of 154 elderly patients with cervical cancer treated at the First Affiliated Hospital of Xian Jiaotong University between February 2018 and February 2021 were enrolled and divided into a combination group (n=77, chemoradiotherapy combined with regional hyperthermia) and a chemoradiotherapy group (n=77, chemoradiotherapy). Short-term therapeutic efficacy (tumor remission rate), serum tumor markers (CEA, SCC, CA125), pain relief rate, incidence of adverse events, and long-term therapeutic outcomes were compared between the two groups. Results Compared with the chemoradiotherapy group, the combination group had a higher tumor remission rate (P<0.05), lower post-treatment serum CEA, SCC, and CA125 levels (P<0.05), and a higher pain relief rate [86.54% (45/52) vs 60.00% (30/50), [χ2]=9.224, P=0.002]. No significant differences were observed in the adverse events between the two groups (P>0.05). The progression-free survival (PFS) of the combination group ranged from 6 to 36 months, with a PFS rate of 23.38%, whereas the PFS of the chemoradiotherapy group was 7 to 36 months, with a PFS rate of 10.39%. Kaplan-Meier survival analysis revealed a statistically significant difference in PFS between the two groups (Log-rank test [χ2]=13.512, P<0.001). The overall survival (OS) of the combination group was 6 to 36 months, with an OS rate of 49.35%, whereas the OS of the chemoradiotherapy group was 7 to 36 months, with an OS rate of 25.97%. Kaplan-Meier survival analysis demonstrated a statistically significant difference in OS between the two groups (Log-rank test [χ2]=21.541, P<0.001). Conclusion The application of chemoradiotherapy combined with regional hyperthermia in elderly patients with cervical cancer can effectively enhance anti-tumor efficacy, reduce serum levels of tumor markers such as CEA, SCC and CA125, relieve the pain, and prolong PFS and OS.
Last Update: 2026-06-26